Effects of Everolimus (Certican) on cardiac hypertrophy and carotid atherosclerosis after kidney transplantation

Trial Profile

Effects of Everolimus (Certican) on cardiac hypertrophy and carotid atherosclerosis after kidney transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Mycophenolate sodium; Prednisone; Tacrolimus
  • Indications Carotid artery diseases; Left ventricular hypertrophy; Renal transplant rejection
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 03 May 2017 Results presented at the 2017 American Transplant Congress
    • 03 May 2017 Status changed from recruiting to completed, according to the results presented at the 2017 American Transplant Congress
    • 17 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top